Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
7
×
boston blog main
life sciences
national blog main
boston top stories
clinical trials
drugs
alnylam pharmaceuticals
fda
national top stories
new york blog main
new york top stories
onpattro
patisiran
rna interference
akcea therapeutics
aminolevulinic acid
givosiran
hereditary transthyretin amyloidosis
inotersen
pfizer
san diego blog main
san diego top stories
svb leerink
tafamidis
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
aldehyde
aldeyra therapeutics
allergic conjunctivitis
allopregnanolone
andrew berens
andrew fire
avapritinib
blueprint medicines
brexanolone
cancer
craig mello
What
drug
7
×
medicine
7
×
fda
alnylam
rnai
interference
new
pharmaceuticals
rna
seek
approval
approved
data
filing
ok
second
specifically
speedy
type
afternoon
ago
aldeyra
alnylam’s
announced
approves
blueprint
brexanolone
cancer
cells
chasing
cleared
closer
deadly
deciphera
depression
devastating
disclosed
disorder
ema
employ
Language
unset
Current search:
medicine
×
drug
×
boston
×
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug